N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
The present invention is directed to N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide of the formula: or a pharmaceutically acceptable salt or stereoisomer thereof, and pharmaceutical compositions comprising the same. The present invention has HIV integrase inhibitory activity.
1. A compound:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
3. A compound:
4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound according to claim 3 .
5. A compound:
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound according to claim 5 .
7. A compound:
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound according to claim 7 , or a pharmaceutically acceptable salt thereof.
9. A compound:
10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound according to claim 9 .
11. A compound:
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent together with the compound according to claim 11 .